Diagnexia and Stratipath link up brings AI breast cancer diagnostics to UK

Collaboration expands AI-based risk profiling tools

Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based prognostic risk profiling tool, to healthcare providers across the UK and Europe.

This collaboration integrates Stratipath’s technology with Diagnexia’s digital pathology network, providing faster, more precise cancer diagnostics. The partnership aims to improve decision-making for breast cancer treatments.

Stratipath Breast analyses routine H&E-stained slides to categorise tumours into high- and low-risk groups. It delivers rapid results in under an hour, reducing costs and increasing accessibility to precision oncology.

Fredrik Wetterhall, CEO of Stratipath, said: “By leveraging AI, more oncologists will have access to faster and more affordable risk stratification tools, enabling quicker treatment decisions and reducing the need for costly gene expression tests.”

Diagnexia plans to expand the reach of AI-based diagnostics, enhancing workflow efficiency and supporting clinicians in treatment decision-making. Donal O’Shea, CEO of Diagnexia, said: “This partnership allows us to bring Stratipath’s groundbreaking risk stratification technology to more patients and clinicians, reducing delays and improving access to personalised cancer diagnostics.”

Stratipath Breast is already in clinical use at several hospitals and complies with EU and UK clinical standards (CE-IVD and UK Rep). It addresses disparities in access by eliminating the need for additional investment, simplifying workflows, and enabling equitable precision diagnostics.

Diagnexia’s digital pathology network connects subspecialty pathologists globally, aligning with its mission to improve diagnostic accuracy and accessibility. The partnership with Stratipath represents a step forward in providing life-saving diagnostic insights to breast cancer patients.

Stratipath Breast will soon be available through Diagnexia’s platform, bringing AI solutions to clinicians and patients across the UK.